Pan Cancer T develops TCR-T cell therapies that utilize genetically modified T cells to target and eliminate tumor cells based on specific intracellular antigens in solid cancers. The company focuses on 30 unique tumor-restricted targets to enhance the durability and efficacy of treatments for hard-to-treat solid tumors, including triple-negative breast cancer.
Funding
$10.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors pose a significant challenge for T-cell therapies due to the limited number of validated tumor-specific targets and the immunosuppressive tumor microenvironment. Current T-cell therapies often struggle to effectively penetrate and persist within solid tumors, leading to limited efficacy and durability.
Solution
Pan Cancer T is developing next-generation TCR-T cell therapies designed to overcome the limitations of current approaches in solid tumor treatment. Their approach centers on a library of 30 novel, intracellular targets exclusively expressed in a range of solid cancers. The company engineers T cells to recognize these targets, enhancing their ability to selectively target and eliminate tumor cells while minimizing off-target effects. Furthermore, Pan Cancer T's augmented T cells are engineered for enhanced durability and resistance to the immunosuppressive tumor microenvironment, promoting deeper and more durable clinical responses.
Target Audience
The primary target audience includes patients with solid tumors, particularly those with limited treatment options or resistance to existing therapies, as well as oncologists and researchers seeking innovative approaches to cancer immunotherapy.
Features
- Utilizes TCR-T therapy, genetically modifying T cells to target specific tumor-associated antigens.
- Focuses on 30 unique, tumor-restricted intracellular targets across 10 solid cancers.
- Engineered T cells designed for enhanced persistence and activity within the tumor microenvironment.
- Lead program targeting triple-negative breast cancer with demonstrated preclinical proof-of-concept.
- Discovery engine for identifying novel tumor targets and highly specific T-cell receptors (TCRs).